The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery

International Anesthesiology Clinics

Volumn 37, Issue 2, 1999, Pages 55-79

  Riedel, Bernhard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; DIGOXIN; ENOXIMONE; ISOPRENALINE; MILRINONE; NITRIC OXIDE; PIROXIMONE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROTAMINE; SIMVASTATIN; TOLAZOLINE;

ARTERIAL OXYGEN TENSION; ASSISTED VENTILATION; HEART SURGERY; HUMAN; LUNG BLOOD VESSEL; LUNG VASOCONSTRICTION; NONHUMAN; PATHOPHYSIOLOGY; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; TREATMENT PLANNING; VASCULAR ENDOTHELIUM;

EID: 0032955883     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-199903720-00005     Document Type: Review

References (141)

1. Wheller J, George BL, Mulder DG, Jarmakani JM. Diagnosis and management of postoperative pulmonary hypertensive crises. Circulation 1979;60:1640-1644
2. Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation 1981;64:873-877
3. Hickey PR, Hansen DD, Wessel DL, et al. Blunting of stress responses in the pulmonary circulation in infants. Anesth Analg 1985;64:1137-1142
4. Kirklin JW, Barrat-Boyes BG. Hypothermia, circulatory arrest and cardiopulmonary bypass. In: Kirklin JW, Barrat-Boyes, eds. Cardiac Surgery. New York: Wiley Medical, 1986:29-82
5. Hickey PR, Hansen DD. Pulmonary hypertension in infants: postoperative management. In: Yacoub M, ed. Annual of cardiac surgery. London: Current Science, 1989:16-22
6. 1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 1985;89:567-572
7. Foubert L, Latimer RD, Oduro A, et al. Use of inhaled nitric oxide to reduce pulmonary hypertension after heart transplantation. J Cardiothorac Vasc Anesth 1993;7:506-507
8. Heerdt PM, Pond CG. Right ventricular pulsatile load and contractility following hypothermic cardiopulmonary bypass in cardiac surgical patients. Anesth Analg 1997;84:S85
9. Mangano D. Biventricular function after myocardial revascularisation in humans: deterioration and recovery patterns during the first 24 hours. Anesthesiology 1985;62:571-577
10. Hines R, Barash P. Intraoperative right ventricular dysfunction detected by a right ventricular ejection fraction catheter. J Clin Monitoring 1986;2:206-208
11. Boldt J, Kling D, Moosdorf R, et al. Influence of acute volume loading on right ventricular function after cardiopulmonary bypass. Crit Care Med 1989;17:518-525
12. Stein K, Breisblatt W, Wolfe C, et al. Depression and recovery of right ventricular function after cardiopulmonary bypass. Crit Care Med 1990;18:1197-1200
13. Cooke JP, Tsao PS. Cytoprotective effect of nitric oxide. Circulation 1993;88:2451-2454
14. Bando K, Pillai R, Cameron DE, et al. Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:873-877
15. Mashburn JP, Kontos GJ, Jr, Hashimoto K, et al. The role of neural and vasoactive mediators in the regulation of the pulmonary circulation during cardiopulmonary preservation. J Thorac Cardiovasc Surg 1989;98:434-443
16. Peterson MB, Huttermeier PC, Zapol WM, et al. Thromboxane mediates acute pulmonary hypertension in sheep extra-corporeal perfusion. Am J Physiol 1982;243:H471-173
17. Greeley WJ, Bushman GA, Kong DL, et al. Effects of cardiopulmonary bypass on eicosanoid metabolism during pediatric cardiovascular surgery. J Thorac Cardiovasc Surg 1988;95:842-849
18. Hopkins RA, Bull C, Sumner E, et al. Pulmonary hypertensive crisis following surgery for congenital heart defects [abstract]. Circulation 1985;72(suppl 3);259
19. Latson TW, Kirckler TS, Baumgartner WA. Pulmonary hypertension and noncardiogenic pulmonary edema following cardiopulmonary bypass associated with an antigranulocyte antibody. Anesthesiology 1986;64:106-111
20. Koul B, Wollmer P, Willen H, et al. Venoarterial extracorporeal membrane oxygenation - how safe is it? J Thorac Cardiovasc Surg 1992;104:579-584
21. Morita K, Ihnken K, Buckberg GD, et al. Pulmonary vasoconstriction due to impaired nitric oxide production after cardiopulmonary bypass. Ann Thorac Surg 1996;61:1775-1780
22. Hynynen M, Saijonmaaa O, Tikkanen I, et al. Increased plasma endothelin immunoreactivity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;103:1024-1025
23. Hashimoto K, Miyamoto H, Suzuki K, et al. Evidence of organ damage after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;104:666-673
24. Matheis G, Haak T, Beyersdorf F, et al. Circulating endothelin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 1995;9:269-274
25. Bando K. Vijay P, Turrentine MW, et al. Dilutional and modified ultrafiltration reduces pulmonary hypertension after operations for congenital heart disease: a prospective randomized study. American Association for Thoracic Surgery 77th Annual Meeting Program 1997:A-54
26. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051
27. Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992;85:1390-1397
28. Turner-Gomes SO, Andrew M, Coles J, et al. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg 1992;103:87-97
29. Rabinovitch M, Andrew M, Thom H, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987;5:1043-1052
30. Marczin N, Ryan US, Catravas JD. Effects of oxidant stress on endothelium-derived relaxing factor-induced and nitrovasodilator-induced cGMP accumulation in vascular cells in culture. Circ Res 1992;70:326-340
31. Haworth SG. Pulmonary vascular disease in different types of congenital heart disease: implications for interpretation of lung biopsy findings in early childhood. Br Heart J 1984;52:557-571
32. Lualdi JC, Goldhalber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 1995;130:1276-1282
33. Koul B, Willen H, Sjoberg T, et al. Pulmonary sequelae of prolonged total venoarterial bypass: evaluation with a new experimental model. Ann Thorac Surg 1991; 51:794-799
34. Anyanwu E, Dittrich H, Gieseking R, Enders HJ. Ultrastructural changes in the human lung following cardiopulmonary bypass. Basic Res Cardiol 1982;77:309-322
35. Lesage AM, Tsuchoika H, Young WG, Jr, Sealy WC. Pathogenesis of pulmonary damage during extracorporeal perfusion. Arch Surg 1966;93:1002-1008
36. Rabinovitch M, Bothwell T, Hayakawa BN, et al. Pulmonary artery endothelial abnormalities in patients with congenial heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986;55:632-653
37. Mazmanian GM, Baudet B, Brink C, et al. Methylene blue potentiates vascular reactivity in rat lungs. J Appl Physiol 1989;66:1040-1045
38. Marshall JJ, Kontos HA. Endothelium-derived relaxing factors: a perspective from in vivo data. Hypertension 1990;16:371-386
39. Watanabe A, Kawaharada N, Kusajima K, et al. Contralateral lung injury associated with single-lung ischemia-reperfusion injury. Ann Thorac Surg 1996;62:1644-1649
40. Barbotin-Larrieu F, Mazmanian M, Baudet B, et al. Prevention of ischemia-reperfusion injury by inhaled nitric oxide in neonatal piglets. J Appl Physiol 1996;80:782-788
41. Tsao PS, Aoki N, Lefer DJ, et al. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990;82:1402-1412
42. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-827
43. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrate: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci 1990;87:1620-1624
44. Weiss SJ, Young J, LoBuglio AF, Slivka A. Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest 1981;68:714-772
45. Maruyama K, Ye CL, Woo M, et al. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol 1991;261:H1716-H1726
46. Todorovich-Hunter L, Johnson DJ, Ranger P, et al. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study. Lab Invest 1988;58:184-195
47. Rabinovitch M, Bothwell T, Hayakawa BN, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986;55:632-653
48. Thompson K, Kobayashi J, Childs T, et al. Endothelial and serum factors which include apolipoprotein A1 tether elastin to smooth muscle cells inducing serine elastase activity via tyrosine kinase-mediated transcription and translation. J Cell Physiol 1998;174:78-89
49. Molossi S, Elices M, Arrhenius T, Rabinovitch M. Lymphocyte transendothelial migration toward smooth muscle cells in interleukin-1 beta-stimulated co-cultures is related to fibronectin interactions with alpha 4 beta 1 and alpha 5 beta 1 integrins. J Cell Physiol 1995;164:620-633
50. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739
51. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995;269:H1186-H1194
52. Maruyama K, Ye CL, Woo M, et al. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol 1991;261:H1716-H1726
53. Chau EM, Bailey KR, Mahoney DW, et al. Predictors of reversibility of pulmonary hypertension in cardiac transplant recipients in the first postoperative year. Circulation 1996;94:II267-272
54. Curling PE, Zaidan JR, Murphy DA, et al. Evaluation of patients with pulmonary hypertension for orthotopic heart transplantation: nitroprusside vs. nitroglycerin. Anesth Analg 1987;66:S-191
55. Schroeder JS. Current status of cardiac transplantation, 1978. JAMA 1979;241:2069
56. Cooper DKC, Novitzky D, Becerra E, Reichart B. Are there indications to heterotopic heart transplantation in 1986? A 2- to 11-year follow up 49 consecutive patients undergoing heterotopic heart transplantation. J Thorac Cardiovasc Surg 1986;34:300
57. Griepp RB, Stinson EB, Dong E, et al. Determinants of operative risk in human heart transplantation. JAMA 1986;255:1892
58. Hastillo A, Hess ML. Selection of patients for cardiac transplantation. Cardiovasc Clin 1990;20:107
59. Kirklin JK, Naftel DC, Kirklin JW, et al. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988;7:331
60. Kormos RL, Thompson M, Hardesty RL, et al. Utility of preoperative right heart catheterisation data as a predictor of survival after heart transplantation. J Heart Transplant 1986;5:391
61. Raikar GV, Hisamochi K, Raikar B-LN, Schaff HV. Nitric oxide inhibition attenuates systemic hypotension produced by protamine. J Thorac Cardiovasc Surg 1996;111:1240-1247
62. Montalescot G, Lowenstein E, Ogeltree ML, et al. Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. Circulation 1990;82:1765-1777
63. Rafferty T, Durkin M, Harris S, et al. Transesophageal two-dimensional echocardiographic analysis of right ventricular systolic performance indices during coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1993;7:160-166
64. Siu SC, Levine RA, Rivera JM, et al. Three-dimensional echocardiography improves non-invasive assessment of left ventricular volume and performance. Am Heart J 1995;130:812-822
65. Wessel DL, Adatia I, Giglia TM, et al. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88:2128-2138
66. Angdin M, Settergren G. Acetylcholine reactivity in the pulmonary artery during open heart surgery in patients with ischemic and/or valvular heart disease. Anesth Analg 1995;80:SCA99
67. Ignarro LJ, Harbison RG, Woods KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986;237:893-900
68. Marczin N, Riedel B, Royston D, Yacoub M. Intravenous nitrate vasodilators and exhaled nitric oxide. Lancet 1997;349:1742
69. Beghetti M, Silkoff PE, Caramori M. et al. Decreased exhaled nitric may be a marker of cardiopulmonary bypass-induced injury. Ann Thorac Surg 1998;66:532-534
70. Marczin N, Riedel B, Gal J, Yacoub M. Exhaled nitric oxide during lung transplantation. Lancet 1997;350:1681
71. Naik S, Balaji S, Elliot M. Modified ultrafiltration improves hemodynamics alter cardiopulmonary bypass in children. JACC 1992;19:37A
72. Naik S, Balaji S, Elliot M. Modified ultrafiltration improves hemodynamics after cardiopulmonary bypass in children. JACC 1992;19:37A
73. Allen BS, Halldorsson A, Kronen M, et al. Controlled reperfusion after lung ischemia: implications for improved function after lung transplantation. American Association for Thoracic Surgery 77th Annual Meeting Program 1997:F10
74. Ricci A, Mariotta S, Greco S, et al. Age-related changes of the noradrenergic innervation of rat tracheobronchial tree and pulmonary vasculature. Mech Ageing Dev 1997;99:245-255
75. Tamaoki J, Tagaya E, Chiyotani A, et al. Effect of adenosine on adrenergic neurotransmission and modulation by endothelium in canine pulmonary artery. Am J Physiol 1997;272:H1100-H1105
76. Blomberg S, Emanuelsson H, Ricksten S-E. Thoracic epidural anesthesia and central haemodynamics in patients with unstable angina. Anesth Analg 1989;69:558-562
77. Liem TH, Booij LH, Hasenbos MA, et al. Coronary artery bypass using two different anesthetic techniques: Part 1: haemodynamic results. J Cardiothorac Vasc Anesth 1992;6:148-155
78. Stenseth R, Bjella L, Berg EM, et al. Thoracic epidural analgesia in aortocoronary bypass surgery I: haemodynamic effects. Acta Anaesthesiol Scand 1994;38:826-833
79. Acuff TE, Landreneau RJ, Griffith BP, Mack MJ. Minimally invasive coronary artery bypass grafting. Ann Thorac Surg 1996;61:135-137
80. Rovetto MJ, Lamberton WF, Neely JR. Mechanisms of glycolytic inhibition in ischemic rat hearts. Circ Res 1975;37:742-751
81. Akimitsu T, White JA, Carden DL, et al. Fructose-1,6-diphosphate or adenosine attenuate leukocyte adherence in postischemic skeletal muscle. Am J Physiol 1995;269:H1743-1751
82. Markov AK, Brumley MA, Figueroa A, et al. Hemodynamic effects of fructose-1,6-diphosphate in patients with normal and impaired left ventricular function. Am Heart J 1997;133:541-549
83. Riedel B, Sacco C, Fox AW, et al. Myocardial performance preservation by fructose-1,6-diphosphate (FDP) following cardiopulmonary bypass. Anesthesiology 1996;85:A505
84. Riedel B, Fox AW, Royston D. Pulmonary endothelial cytoprotection by fructose-1,6-diphosphate in cardiac surgery [abstract]. Br J Anesthesiol 1998;80(suppl 1):A193
85. Kretzschmar M, Klein U, Palutke M, Schirrmeister W. Reduction of ischemia-reperfusion syndrome after abdominal aortic aneurysmectomy by N-acetylcysteine but not mannitol. Acta Anaesthesiol Scand 1996;40:657-664
86. Kawamura T, Wakusawa R, Okada K, Inada S. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin-8 and 6 in reperfusion injury. Can J Anaesth 1993;40:1016-1021
87. Oz MC, Liao H, Naka Y, et al. Ischemia-induced interleukin-8 release after human heart transplantation: a potential role for endothelial cells. Circulation 1995;92(suppl II):428-432
88. Schmitz ML, Baeuerle PA. Multi-step activation of NF-kappaB/Rel transcription factors. Immunobiology 1995;193:116-127
89. Schranz D, Zepp F, Iversen S, et al. Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 1992;20:1243-1249
90. Fullerton DA, Kirson LE, Cur JA, et al. The influence of respiratory acid-base status on adult pulmonary vascular resistance before and after cardiopulmonary bypass. Chest 1993;103:1091
91. Berner M, Oberhansli I, Rouge JC, et al. Chronotropic and inotropic supports are both required to increase cardiac output early after corrective operations for tetralogy of Fallot. J Thorac Cardiovasc Surg 1989;97:297
92. Aronson S, Wiencek JG. Intraoperative perfusion echocardiography. J Cardiothorac Vasc Anesth 1994;8:97-107
93. Meza MF, Mobarek S, Sonnemaker R, et al. Myocardial contrast echocardiography in human beings: correlation of resting perfusion defects to sestamibi single photon emission computed tomography. Am Heart J 1996;132:528-535
94. Doyle AR, Dhir AK, Moors AH, Latimer RD. Treatment of perioperative low cardiac output syndrome. Ann Thorac Surg 1995;59:311
95. Molloy DW. Effects of noradrenaline and isoproterenol on cardiopulmonary function in a canine model of acute pulmonary hypertension. Chest 1985;88:432
96. Stevenson DK, Kasting DS, Darnall RA, et al. Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline. J Pediatr 1979; 95:595-599
97. 2 reverses induced pulmonary hypertension in the newborn lamb. J Pediatr 1982;100:458-463
98. Saji T, Ozawa Y, Ishikita T, et al. Short term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996;78:244-247
99. Estrada-Quintero T, Uretsky BF, Murali S, et al. Neurohumoral activation and exercise function in patients with severe heart failure and patients with left ventricular assist system. Chest 1995;107:1499-1503
100. Cueto E, Lopez-Herce J, Sanchez A, Carillo A. Life-threatening effects of discontinuing inhaled nitric oxide in children. Acta Paediatr 1997;86:1337-1339
101. Szabo C. The role of peroxynitrite in the pathophysiology of shock, inflammation, and ischemia-reperfusion injury. Shock 1996;6:79-88
102. Szabo C, Zingarelli B, Salzman AL. Role of poly-ADP ribosyltransferase activation in the nitric oxide- and peroxynitrite-induced vascular failure. Circ Res 78:1051-1060
103. Barbotin-Larrieu F, Mazmanian M, Baudet B, et al. Prevention of ischemia-reperfusion injury by inhaled nitric oxide in neonatal piglets. J Appl Physiol 1996;80:782-788
104. Murakami S, Bacha EA, Hervæ P, et al. Prevention of reperfusion injury by inhaled nitric oxide in lungs harvested from non-heart beating donors. Ann Thorac Surg 1996;62:1632-1638
105. Naka Y, Roy DK, Smerling AJ, et al. Inhaled nitric oxide fails to confer the pulmonary protection provided by distal stimulation of the nitric oxide pathway at the level of cyclic guanosine monophosphate. J Thorac Cardiovasc Surg 1995;110:1434-1441
106. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719
107. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493
108. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131
109. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998;95:8880-8885
110. Kaneko S, Watananbe S, Kano T. Effects of human atrial natriuretic peptide on hemodynamics and pulmonary gas exchanges in cardiac surgery patients. Masui 1997;46:1487-1491
111. Morikawa E, Moskowitz MA, Huang Z, et al. L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke 1994;25:429-435
112. Coleman RA, Smith WL, Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205-229
113. 2 inhibit ET-1 secretion from endothelial cells by stimulating particulate guanylate cyclase. Am J Physiol 1996;270: H1342-H1349
114. Goldman AP, Delius RE, Deanfield JE, Macrae DJ. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 1995;60:300-306
115. Haraldsson A, Kieler-Jensen N, Ricksten S-E. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth 1996;10:864-868
116. Zwissler B, Weite M, Messmer K. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vasc Anesth 1995;9:283-289
117. Eichelbronner O, Reinelt H, Wiedeck H, et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock-different effects on splanchnic oxygenation? Intens Care Med 1996;22:880-887
118. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:991-996
119. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Am Intern Med 1996;124:820-824
120. Pappert D, Busch T, Gerlach H, et al. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995;82:1507-1511
121. Zwissler B, Rank N, Jaenicke U, et al. Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass. Anesthesiology 1995;82:1512-1516
122. Zobel G. Dacar D, Rodl S, Friehs I. Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Res 1995;38:198-204
123. Hausdorf G, Morf G, Berdjis F, et al. Postoperative pulmonary hypertension in children with congenital heart disease. Z Herz-, Thorax-, Gefasschir 1992;6:318-322
124. Waurick R, Bone HG, Meyer J, et al. Inhalative vasodilators in ovine pulmonary hypertension. Anesth Analg 1997;84:S596
125. Kveder R. Use of prostacyclin as the only anticoagulant during continuous venovenous hemofiltration. In: Siebert HG, Mann H, Stummvoll HK, eds. Continuous hemofiltration. Karger, Basel, 1991:218-220
126. 2. J Appl Physiol 1988; 80:191-197
127. Boldt J, Kling D, Zickmann B, et al. Efficacy of the phosphodiesterase inhibitor enoximone in complicated cardiac surgery. Chest 1990;98:53-58
128. Lee T-S, Hou X. Comparative vasoactive effects of amrinone on systemic and pulmonary arteries in rabbits. Chest 1995;108:1364-1367
129. Wessel DL, Triedman JK, Wernovsky G, et al. Pulmonary and systemic hemodynamics of amrinone in neonates following cardiopulmonary bypass. Circulation 1989;80 (suppl II):II-488
130. Konstam MA, Cohen SR, Salem DN, et al. Effect of amrinone on right ventricular function: predominance of after load reduction. Circulation 1986;74:359
131. Doolan LA, Jones EF, Kalman J, et al. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from CPB. J Cardiothorac Vasc Anesth 1997;11:37-41
132. Monrad ES, McKay RG, Bairn DS, et al. Improvement in the indices of diastolic performance in patients with congestive heart failure with milrinone. Circulation 1984;70:1030-1037
133. Erhardt PW, Hagedorn AA, Sabio M. Cardiotonic agents 3. A topographical model of the cardiac cAMP phosphodiesterase receptor. Mol Pharmacol 1988;33:1-13
134. Gao Y, Sauro MD, Hakim TS, Camporesi EM. ATP-induced endothelium dependent relaxation of rat pulmonary arteries is partially mediated by P2y receptors. Anesthesiology 1996;85:A1138
135. Fullerton DA, Jones SD, Grove, FL, McIntyre RC, Jr. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg 1996;61:1118-1124
136. Zall S, Milocco I, Rickstein S-E. Effects of adenosine on myocardial blood flow and metabolism after coronary artery bypass surgery. Anesth Analg 1991;73:689
137. Nagata N, Kitamura K, Kato J, et al. The effect of hypothermic cardiopulmonary bypass on plasma adrenomedullin in adult cardiac surgical patients. Anesth Analg 1997;84:1193-1197
138. Nossaman BD, Feng CJ, Kaye AD, et al. Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats. Am J Physiol 1996;270:L782-789
139. Hessel EA. Cardiopulmonary bypass equipment and circulatory assist devices. In: Estafanous FG, Barash PG, Reves JG, eds. Cardiac anesthesia. 1994:241-292
140. Jones RL, St. Cyr JA, Tornabene SP, et al. Reversible pulmonary hypertension secondary to mitral valvular disease as an indication for extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 1991;5:494-497
141. Yano M, Onitsuka T, Koga Y. Efficacy and safety of percutaneous right ventricular assist system. Ann Thorac Surg 1996;61:1231-1235